

1. Has the deployment of COVID-19 vaccine "Corminaty" started in your countries? Yes/No – if no, please explain why not and for when the roll-out is planned.
2. How many persons have been vaccinated already? Please specify number (as of date/time)
3. Have you encountered any important logistical or other challenges? Yes/No – if yes, please specify.
4. Are there key questions related to COVID-19 vaccines / the vaccination roll-out you would like to discuss?

@ 5.1.2e zou jij wellicht input kunnen sturen rondom nieuwe SARS-CoV-2 variant m.b.t. snelle identificatie nieuwe varianten (*fast identification of new critical variants*) en raamwerk voor hun karakteristieken (*framework for their characterisation*)? Graag ontvang ik hiervoor ook einde morgen werkdag input zodat ik deze kan voorbereiden. Als ik hiervoor bij iemand anders moet zijn, dan hoor ik het ook graag.

@ 5.1.2e CTC, wie kan ik verder benaderen voor de vraag m.b.t. nieuwe SARS-CoV-2 variant? Met name onze maatregelen hierop.

Hartelijke groet,

5.1.2e

Van: 5.1.2e, 5.1.2e, (5.1.2e) < 5.1.2e @minvws.nl >

Verzonden: maandag 4 januari 2021 17:17

Aan: 5.1.2e, 5.1.2e, 5.1.2e < 5.1.2e @minvws.nl >

Onderwerp: FW: Invitation to a joint HSC/EU NITAG COLLABORATION meeting Wednesday Jan 6, 14.30 - 16.30

Van: 5.1.2e @ec.europa.eu

Verzonden: maandag 4 januari 2021 17:17:04 (UTC+01:00) Amsterdam, Berlijn, Bern, Rome, Stockholm, Wenen

Aan: 5.1.2e @ec.europa.eu

Onderwerp: Invitation to a joint HSC/EU NITAG COLLABORATION meeting Wednesday Jan 6, 14.30 - 16.30

Dear HSC Members and Observers, dear members of the NITAG collaboration,

We would like to invite you to the 2nd joint meeting of the HSC and NITAGs on Wed 6 Jan from 14:30 – 16:30.

Please register using this link:

<https://europaevent.webex.com/europaevent/onstage/g.php?MTID=e32dafa67d7199e457f46d86da766cb28>

In order to better prepare for the meeting we would like to ask you to **please reply to the following questions in writing before the meeting:**

1. Has the deployment of COVID-19 vaccine "Corminaty" started in your countries? Yes/No – if no, please explain why not and for when the roll-out is planned.
2. How many persons have been vaccinated already? Please specify number (as of date/time)
3. Have you encountered any important logistical or other challenges? Yes/No – if yes, please specify.
4. Are there key questions related to COVID-19 vaccines / the vaccination roll-out you would like to discuss?

Please see draft agenda below:

Draft agenda

Time: Wednesday Jan 6, 14:30-16:30 CET

Co-chairs: 5.1.2e (SANTE C3) and 5.1.2e 5.1.2e (ECDC)

1. New SARS-CoV-2 variants of concern		
14:30 – 14:35	Welcome and Objectives of the meeting	Dubbel 5.1.2e EC SANTE C3/5.1.2e, ECDC
14:35 – 14:50	Spread of the UK-variant of SARS-CoV2 in the UK – up-date, recommendations for response	5.1.2e 5.1.2e, PHE, UK (tbc)
14:50 – 14:55	Questions	
14:55 – 15:05	DK - UK variant identified in up to 5% of sequenced samples in Northern Jutland and Zealand	5.1.2e and 5.1.2e, SSI, Denmark
15:05 – 15:10	Questions	

15:10 – 15:20	ECDC RRA – Europe and global up-date on SARS-CoV-2 variants of concern (South African and UK variants), recommendations for response, fast identification of new critical variants and framework for their characterisation	5.1.2e 5.1.2e 5.1.2e 5.1.2e
15:20 – 15:30	Discussion	All
2. COVID-19 vaccines and vaccinations		
15:30 – 15:40	EMA: up-date on COVID - 19 vaccines in general and their authorisation processes, up date on mRNA vaccines in view of recent changes in the UK schedule, state of play in general on possible need for booster doses or updates of vaccines if needed	5.1.2e 5.1.2e EMA
15:40 – 15:45	Questions	
15:45 – 15:55	WHO – SAGE recommendations for COVID-19 vaccination: summary from meeting on 5 Jan	5.1.2e 5.1.2e THL, Finland (tbc)
15:55 – 16:00	Questions	
16:00 – 16:20	Tour de table (HSC Members/EU NITAG COLL Members jointly): reports from countries on the roll-out: challenges, vaccination strategy implementation (1st and 2nd dose)	
16:20 – 16:30	Discussion	All
16:30	Conclusions & Next steps	5.1.2e and 5.1.2e 5.1.2e

Kind regards,

HSC Secretariat